Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 4/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25337718 | 1.00 | GPR119 (0.47) | GPR119DDB1CRBNMAP4K4PIK3CA | |
| SCHEMBL26683989 | 0.86 | MGLL (0.44) | GPR119DDB1CRBNMGLL | |
| SCHEMBL26842027 | 0.84 | DDB1 (0.44) | GPR119DDB1CRBNLMNASMN1; SMN2 | |
| SCHEMBL26684246 | 0.82 | GPR119 (0.43) | GPR119DDB1CRBNSMN1; SMN2 | |
| SCHEMBL30688284 | 0.82 | GPR119 (0.43) | GPR119DDB1CRBNSMN1; SMN2 | |
| SCHEMBL31349361 | 0.80 | MAP4K4 (0.50) | GPR119MAP4K4PIK3CA | |
| SCHEMBL22119507 | 0.80 | DDB1 (0.59) | GPR119DDB1CRBNLMNAHTT | |
| SCHEMBL26848888 | 0.80 | DDB1 (0.43) | DDB1CRBNLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL30688281 | 0.80 | DDB1 (0.43) | DDB1CRBNLMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL31569884 | 0.80 | DDB1 (0.58) | GPR119DDB1CRBNMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| EP-4221756-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2023-08-09 | — | — | EP | disclosed |
| WO-2022069520-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2022-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | GPR119 2044/4885DDB1 4162/4885CRBN 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.